Table 1 Baseline and on-treatment characteristics of the study cohort
Characteristics | Total | CR (+) | CR (−) | p value |
|---|---|---|---|---|
No. of patients | 171 | 33 (19.3) | 138 (80.7) | |
Age (years) | 28.5 (7.9) | 26.7 (7.6) | 28.9 (7.9) | 0.09 |
Gender (male) | 130/171 (76.0) | 24/33 (72.7) | 106/138 (76.8) | 0.62 |
BMI | 22.2 (3.2) | 22.0 (2.9) | 22.2 (3.3) | 0.71 |
Years of HBV Exposure | 11.2 (9.3) | 7.8 (5.5) | 12.0 (9.8) | 0.02 |
HBV Genotype | ||||
B | 77 | 14 (42.4) | 63 (45.7) | 0.74 |
C | 94 | 19 (57.6) | 75 (54.3) | |
ALT (*ULN) | 4.0 (1.9) | 4.6 (2.3) | 3.8 (1.8) | 0.05 |
ALT > 5*ULN | 35/171 (20.5) | 10/33 (30.3) | 25/138 (18.1) | 0.12 |
HBsAg (Log10 IU/mL) | 4.2 (0.6) | 4.0 (0.6) | 4.3 (0.6) | 0.01 |
HBeAg (Log10 IU/mL) | 2.6 (0.6) | 2.4 (0.6) | 2.6 (0.6) | 0.09 |
HBV DNA (Log10 IU/mL) | 7.8 (0.8) | 7.7 (0.7) | 7.8 (0.8) | 0.44 |
On-treatment Quantifications, week 12 | ||||
HBsAg decrease > 1.5Log | 12/171 (7.0) | 5/33 (15.2) | 7/138 (5.1) | 0.04 |
HBeAg decrease > 1.5Log | 46/171 (26.9) | 15/33 (45.5) | 31/138 (22.5) | 0.01 |
HBV DNA decrease > 2.0Log | 51/171 (29.8) | 18/33 (54.5) | 33/138 (23.9) | <0.01 |
On-treatment Quantifications, week 24 | ||||
HBsAg decrease > 1.5Log | 30/171 (17.5) | 10/33 (30.3) | 20/138 (14.5) | 0.03 |
HBeAg decrease > 1.5Log | 69/171 (40.4) | 23/33 (69.7) | 46/138 (33.3) | <0.01 |
HBV DNA decrease > 2.0Log | 77/171 (45.0) | 24/33 (72.7) | 53/138 (38.4) | <0.01 |